FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:
FSD Pharma Inc.（納斯達克股票代碼：HUGE）（CSE: HUGE）（FRA: 0K9A）（“FSD Pharma”）是一家致力於建立創新資產和生物技術解決方案組合以解決影響全球數百萬人的疾病的生物製藥公司，今天宣佈，2024年6月27日，美國賓夕法尼亞東區地方法院確認了FSD Pharma, Inc.'的判決動議獲得批准，並作出了有利於FSD Pharma和不利於Raza Bokhari博士的判決，判決如下：
- USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $15,000.00, plus interest at a rate of 4% per annum from March 1, 2023 until the date the Judgment is satisfied.
- CAD $2,814,229.15, plus interest at a rate of 6% per annum from May 7, 2023 until the date the Judgment is satisfied.
- 147,301.04美元，外加從2022年11月9日起至判決完成之日按每年4％的利率支付的利息。
- 31,912.55加元，外加從2022年11月9日起至判決完成之日起每年4％的利息。
- 15,000.00加元，外加從2023年3月1日起至判決完成之日起每年4％的利息。
- 2,814,229.15加元，外加從2023年5月7日起至判決完成之日按每年6％的利率支付的利息。
In July 2021, FSD's board of directors terminated Dr. Raza Bokhari, its former CEO. Dr. Raza Bokhari filed an arbitration challenging this termination in Ontario, Canada. After years of litigation and an eight-day evidentiary hearing, the Arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD's fees and costs incurred in the arbitration.
2021 年 7 月，FSD 董事會解僱了其前首席執行官 Raza Bokhari 博哈里博士。Raza Bokhari博士在加拿大安大略省提起仲裁，質疑此次終止。經過多年的訴訟和爲期八天的證詞聽證會，仲裁員對Raza Bokhari博士作出了不利的裁決，並對Raza Bokhari博士做出了三項有利於FSD的裁決，包括一項損害賠償裁決和對FSD在仲裁中產生的費用和成本的裁決。
FSD's Petition to Confirm the Arbitration Awards was filed May 29, 2024 in the United States District Court for the Eastern District of Pennsylvania under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards, June 10, 1958, 21 U.S.T. 2517, 330 U.N.T.S. 3 (the "New York Convention"). In its opinion granting FSD's Petition, the District Court found that Dr. Raza Bokhari did not offer any valid basis under the New York Convention for the Court to deny enforcement of the arbitration awards against him.
FSD根據1958年6月10日的《承認及執行外國仲裁裁決公約》（21 U.S.T. 2517、330 U.N.T.S. 3）（“紐約公約”），於2024年5月29日向美國賓夕法尼亞東區地方法院提交了確認仲裁裁決的申請。地方法院在批准FSD申請的意見中認定，Raza Bokhari博士沒有根據《紐約公約》爲法院拒絕執行鍼對他的仲裁裁決提供任何有效依據。
FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.
FSD將盡一切可能向Medicus Pharma Ltd現任董事長兼首席執行官拉扎·博哈里博士收款。